SAGES Magazine

See what Creon ® can bring to the table Smart digestion in PEI 1,2,3 The only PERT with >5 million patient treatment years of experience 4 Effective substitution of pancreatic enzymes if they are deficient 2 References: 1. Domínguez-Muñoz JE. Pancreatic exocrine insufficiency: diagnosis and treatment. J Gastroenterol Hepatol 2011;26 Suppl 2:12–16. 2. Creon ® 25000. Approved package insert February 2016. 3. Creon ® 10000. Approved package insert September 2005. 4. Solvay Pharmaceuticals. NDA 20-725 for Creon ® (Pancrelipase Delayed-release Capsules) Briefing Document for December 2, 2008 Antiviral Drugs Advisory Committee. S1 Creon ® 10000. Each capsule contains enteric coated granules of Pancreatin 150 mg. S1 Creon ® 25000. Each capsule contains enteric coated granules of Pancreatin 300 mg. Registration Numbers: Mauritius Namibia South Africa Creon ® 10000 R7435/02/16 04/11.1/1015 33/11.1/0340 Creon ® 25000 - 04/11.1/1016 28/11.1/0645 For full prescribing information refer to the package insert approved by the Medicines Regulatory Authority. Abbott Laboratories S.A. (Pty) Ltd. 1940/014043/07. Abbott Place, 219 Golf Club Terrace, Constantia Kloof, 1709. Tel: (011) 858 2000. Publication Date: April 2018. Promotional review number: ZAECRE170148a Creon ® is indicated as a supplement for pancreatic exocrine insufficiency which may be caused by chronic pancreatitis, cystic fibrosis and partial pancreatectomy. 2 PEI - pancreatic exocrine insufficiency; PERT - pancreatic enzyme replacement therapy Pancreatic Enzyme Replacement Therapy PROTEINS CARBS FATS 12797